Processa Pharmaceuticals

PCSA NASDAQ IPO2013

about PCSA

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company that develops "Next Generation Chemotherapy" by re-engineering FDA-approved cancer drugs to improve their safety and effectiveness.

type open high low market
cap
volume
stock $3.35 $8.88 $3.28 $272.35K 39.59M
eps price to
earnings
price to
sales
operating
margin
profit
margin
yield
-$0.07 n/a n/a 0% 0% 0%